TAVO™ + Electroporation (EP) Gene Delivery

We are developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer.  We have built a deep clinical pipeline utilizing our primary technology, TAVO™ (tavokinogene telseplasmid) as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors.  TAVO has the potential to become the first approved therapeutic to address a great unmet medical need: anti-PD-1 non-responders.

TAVO is DNA-based interleukin-12 (IL-12), a naturally occurring protein in the body with immune-stimulating functions. We believe TAVO is administered directly into the tumor using our proprietary electroporation (EP) gene delivery system, which employs a series of momentary energy pulses.  Those pulses are designed to increase the permeability of the cell membrane and facilitate uptake of IL-12 coded DNA into cells.  This non-invasive method is easy to perform and avoids systemic toxicity issues historically associated with IL-12 usage.

Clinical studies have demonstrated that TAVO induces local expression of IL-12, converting immunologically suppressed “cold tumors” into T-cell inflamed “hot tumors” which is fundamental to generating objective responses in both treated and untreated distant tumors.

TAVO is being studied in multiple clinical trials, including a registration-directed pivotal Phase 2 trial in metastatic melanoma and two Phase 2 trials in triple negative breast cancer (TNBC) and head and neck cancer.  Results from recently completed clinical studies of TAVO have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach.

OncoSec’s TAVO: Learn From Physicians and Patients How It Works

OncoSec’s TAVO™ plus Electroporation Gene Delivery: Learn From Physicians and Patients How It Works

Key Highlights Include

Safety Profile

In clinical studies, TAVO has shown a favorable safety profile to date and has been generally well-tolerated across multiple treatment cycles.

Anti-Tumor Activity with Abscopal Effect

Data from our Phase II melanoma program provide preliminary evidence of anti-tumor activity with a whole body (abscopal) effect, paving the way for expansion of our immuno-oncology pipeline.

Cold to Hot

Data indicates that local delivery and expression of TAVO promotes tumor immunogenicity and increases tumor-infiltrating lymphocytes (TILs). As a pro-inflammatory cytokine, IL-12 can promote the recruitment of T-cells to the tumor. By driving T-cells or TILs into the tumor microenvironment, TAVO may enhance response to anti-PD-1 and convert anti-PD-1 non-responders to responders.

How It’s Designed to Work

Roll over images to reveal how TAVO is designed to work.

Step 1

Cancer is identified in the body.

Step 2

DNA-based interleukin-12 (IL-12), a naturally occurring protein, is injected directly into the tumor.

Step 3

The applicator supplies a sequence of short-duration electrical pulses through a series of needles.

Step 4

Electrical pulses result in increased permeability of the cell membrane, allowing DNA-based IL-12 to enter.

Step 5

DNA-based IL-12 is expressed in the local tumor microenvironment.

Step 6

Immune cells are educated to recognize the patient’s cancer.

Step 7

Immune cells are educated to recognize the patient’s cancer.

Step 8

Educated immune cells identify and attack tumors throughout the body.


Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer.



We are committed to sharing the results of our research and clinical development programs.


Visceral Lesion Applicator

OncoSec’s investigational VLA is designed to treat non-cutaneous tumors through direct delivery of TAVO.